Scholarlink

Objective <p>To evaluate the clinical significance of serum response factor (SRF) expression and its association with microvascular density (MVD) and postoperative recurrence in glioblastoma (GBM) patients.</p> Methods <p>This retrospective study included 92 patients with pathologically confirmed GBM who underwent surgical resection between July 2021 and July 2023. Tumor and adjacent normal brain tissues were analyzed via immunohistochemistry to assess SRF expression and CD105-labeled MVD. Spearman’s correlation was used to determine the association between SRF and MVD. Postoperative recurrence was monitored for 12&#xa0;months, and multivariate logistic regression was conducted to identify independent predictors of recurrence.</p> Results <p>SRF was positively expressed in 56.5% of tumor samples, significantly higher than in adjacent normal tissue (2.2%,&#xa0;P &lt; 0.001). SRF-positive tumors demonstrated increased MVD compared to SRF-negative tumors (86.79 ± 14.12 vs. 70.58 ± 8.77 vessels/field,&#xa0;P &lt; 0.05). A strong positive correlation was found between SRF expression and MVD (r = 0.749,&#xa0;P &lt; 0.05). At 1-year follow-up, 24 patients (26.1%) experienced recurrence. SRF positivity, tumor diameter ≥ 5&#xa0;cm, poor differentiation, high histological grade, and incomplete resection were significantly associated with recurrence (all P &lt; 0.05). Multivariate analysis confirmed these as independent predictors (all P &lt; 0.01).</p> Conclusion <p>SRF is overexpressed in glioblastoma and closely linked to tumor angiogenesis and postoperative recurrence. High SRF expression may promote tumor progression through vascular remodeling, suggesting its potential utility as a prognostic biomarker and therapeutic target in GBM management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Serum response factor as a prognostic indicator of angiogenesis and early recurrence in Glioblastoma: a retrospective immunohistochemical study

  • 期刊论文

  • 发表日期：

    2025年8月3日

查看全文
  • Bo Tan,
  • Yaohui Huang,
  • Tao Chen,
  • Peng Song,
  • Shuangyin He,
  • Xiaohong Yin

摘要

Objective

To evaluate the clinical significance of serum response factor (SRF) expression and its association with microvascular density (MVD) and postoperative recurrence in glioblastoma (GBM) patients.

Methods

This retrospective study included 92 patients with pathologically confirmed GBM who underwent surgical resection between July 2021 and July 2023. Tumor and adjacent normal brain tissues were analyzed via immunohistochemistry to assess SRF expression and CD105-labeled MVD. Spearman’s correlation was used to determine the association between SRF and MVD. Postoperative recurrence was monitored for 12 months, and multivariate logistic regression was conducted to identify independent predictors of recurrence.

Results

SRF was positively expressed in 56.5% of tumor samples, significantly higher than in adjacent normal tissue (2.2%, P < 0.001). SRF-positive tumors demonstrated increased MVD compared to SRF-negative tumors (86.79 ± 14.12 vs. 70.58 ± 8.77 vessels/field, P < 0.05). A strong positive correlation was found between SRF expression and MVD (r = 0.749, P < 0.05). At 1-year follow-up, 24 patients (26.1%) experienced recurrence. SRF positivity, tumor diameter ≥ 5 cm, poor differentiation, high histological grade, and incomplete resection were significantly associated with recurrence (all P < 0.05). Multivariate analysis confirmed these as independent predictors (all P < 0.01).

Conclusion

SRF is overexpressed in glioblastoma and closely linked to tumor angiogenesis and postoperative recurrence. High SRF expression may promote tumor progression through vascular remodeling, suggesting its potential utility as a prognostic biomarker and therapeutic target in GBM management.